Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Fulgent Genetics, |
RCV005026515 | SCV005663651 | pathogenic | 3-Oxo-5 alpha-steroid delta 4-dehydrogenase deficiency | 2024-06-13 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV005026515 | SCV005834303 | pathogenic | 3-Oxo-5 alpha-steroid delta 4-dehydrogenase deficiency | 2024-03-16 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Leu111Hisfs*24) in the SRD5A2 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in SRD5A2 are known to be pathogenic (PMID: 1406794, 1944596). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with steroid-5 alpha-reductase deficiency (PMID: 1522235). This variant is also known as delTC at nucleotide 359. For these reasons, this variant has been classified as Pathogenic. |